S 1096 · introduced · significant
Preserve Access to Affordable Generics and Biosimilars Act
- economy
What this bill does
- This bill bans drug manufacturers from settling patent disputes in ways that block generic or biosimilar drugs from the market.
- Generic drug makers and biosimilar producers are affected, along with brand-name pharmaceutical companies.
- The FTC enforces the rule; violators lose their 180-day marketing exclusivity period for generic drugs.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How would removing the ability to settle patent disputes affect the speed at which affordable generic drugs reach patients?
- 02
What would happen to pharmaceutical companies' incentive to invest in new drug development if they lose exclusivity rights after patent settlements?
- 03
Which groups—patients, insurers, generic manufacturers, or brand-name companies—would benefit most from eliminating these settlement agreements?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · D-MN
Amy Klobuchar
Citizen cosponsors
0
In Congress
8/ 100
Senators cosponsoring
Introduced 2025-04-10
Joining the bill
Legislative timeline
2025-04-10 · senate · Calendars
Placed on Senate Legislative Calendar under General Orders. Calendar No. 46.
2025-04-10 · senate · Committee
Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.
2025-04-10 · Committee
Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.
2025-04-03 · senate · Committee
Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
2025-03-24 · senate · IntroReferral
Read twice and referred to the Committee on the Judiciary.
2025-03-24 · IntroReferral
Introduced in Senate
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.